Research Article
The Wound Healing Effect of Doxycycline after Corneal Alkali Burn in Rats

Qiong Yi and Wen-jin Zou

Department of Ophthalmology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, China

Correspondence should be addressed to Wen-jin Zou; bigstone168@163.com

Received 9 April 2019; Revised 16 August 2019; Accepted 17 September 2019; Published 10 October 2019

Academic Editor: Marta Sacchetti

Copyright © 2019 Qiong Yi and Wen-jin Zou. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To evaluate the wound healing effect of doxycycline and its underlying mechanisms in a rat model of corneal alkali burn.

Methods. Male SD rats were administered 1.0 N NaOH in the right cornea for 25 seconds and randomly divided into the doxycycline group and the control group, with 84 rats in each group. 1.0 g·L⁻¹ doxycycline eye drops (doxycycline group) or vehicle (control group) was topically instilled onto the rat cornea after chemical injury. Three days, 7 days, and 14 days after alkali burn, microscopy was used to observe corneal wound healing by fluorescein staining and the degree of corneal opacity. The expression of transforming growth factor-beta 1 (TGF-β1) and matrix metalloproteinase-9 (MMP-9) was detected by RT-PCR and ELISA, alpha-smooth muscle actin (α-SMA) levels were measured by immunofluorescent staining, and Western blot assays for TGF-β1, α-SMA, and nuclear factor-kappa B (NF-κB) were also performed.

Results. Corneal wound healing and corneal opacity scores were better in the doxycycline group than in the control group. Three, 7, and 14 days after corneal alkali burn, a significant increase in TGF-β1 was observed in corneas from the control group, compared with the corneas from the doxycycline group (P < 0.05). The corneal levels of MMP-9 in the doxycycline group were lower than those in the control group 3 days and 7 days after alkali burn (P < 0.05). In addition, doxycycline inhibited α-SMA expression and suppressed NF-κB expression.

Conclusion. Doxycycline treatment promoted corneal healing and reduced corneal opacity in SD rats. Doxycycline protected the cornea from alkali burn injury by reducing TGF-β1, MMP-9, NF-κB, and α-SMA expression.

1. Introduction

Chemical injury of the eye is a common intractable ocular disease in the clinic. Slow epithelialization, persistent ulceration, corneal perforation, neovascularization (NV), and opacification are the main complications, and chemical injury of the eye may cause permanent visual impairment or blindness [1, 2]. Keratocyte activation, myofibroblast formation, and tissue fibrosis all participate in the wound healing process or scar formation in the cornea after alkali burn [3, 4]. Therefore, corneal scars may be reduced by inhibiting all or one of the above three processes.

Normal corneal keratocytes are stationary and help maintain corneal transparency; nevertheless, after corneal injury, the disruption of corneal integrity induces quiescent keratocytes to differentiate into active myofibroblasts [5]. The morphology of corneal myofibroblasts is different than that of keratocytes, and corneal myofibroblasts are defined by their unique expression of alpha-smooth muscle actin (α-SMA) [6]. Among the many cytokines and growth factors that affect the corneal wound healing reaction, transforming growth factor-β1 (TGF-β1) plays an important role in the regeneration of damaged tissue [7, 8]. After corneal alkali burn, TGF-β1 has been shown to be upregulated and induce the differentiation of keratocytes to myofibroblasts, which contributes to the recovery of the cornea [9, 10]. TGF-β1 has also been reported as an effective chemotactic factor for monocytes, neutrophils, and macrophages [11, 12]. During the inflammatory response, TGF-β1 has been found to stimulate the expression of MMP-9 in the cornea [13]. In addition, NF-κB competes with TGF-β1 to control the expression of MMPs [14], and the degradation of the basement
membrane by MMP-9 is known to contribute to the promotion of pathogenic ulcers and the perforation of the corneal stroma [15]. NF-κB is mediated angiogenesis, which affects the transparency of the cornea [16]. The overexpression of TGF-β1 has been shown to induce the accumulation of myofibroblasts, and this is believed to be a major mechanism of corneal opacification after damage, as myofibroblasts exhibit a different crystalline production and are, consequently, opaquer than keratocytes [17].

Doxycycline (Doxy) was discovered in the early 1960s as a long-acting, low-cost, semisynthetic tetracycline antibiotic that has a broad-spectrum antibacterial effect [18]. Doxycycline has attracted much attention due to its use in the treatment of various diseases such as pulmonary fibrosis, nasal polyps, and chronic periodontitis [19–21]. In addition, doxycycline has been reported to inhibit the remodeling of skin fibroblasts and human conjunctival fibroblasts [22, 23]. In treating corneal diseases, tetracyclines inhibit the collagenolytic degradation of the cornea resulting from chemical injury and other noninfectious corneal ulcers by inhibiting MMP activity [24]. It has been reported that doxycycline may reduce the formation of corneal scars by inhibiting the infiltration of inflammatory cells and neovascularization after corneal alkali burn in rats [25, 26]. However, the effect of doxycycline in corneal scarring and the underlying molecular mechanism are still unclear. In this study, we aimed to evaluate the effect of doxycycline on corneal wound healing and the associated mechanism after alkali burn.

2. Materials and Methods

2.1. Animals. All animals were treated according to the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research, and the procedures were approved by the Guangxi Medical University of Medicine Institutional Animal Care and Use Committee. Eighty-four male Sprague-Dawley (SD) rats (body weight range, 180–220 g) were divided into two groups, with 42 rats in each group.

2.2. In Vivo Animal Model of Corneal Chemical Burn Injury. Before the establishment of the alkali burn model, an antibiotic (0.3% tobramycin eye drops) was administered 4 times a day to prevent corneal infection, and the presence of disease of the anterior segment was checked with a slit lamp before the experiment. The rats were anaesthetized by an intraperitoneal injection of ketamine (40 mg/kg)/xylazine (8 mg/kg). Using tetracaine hydrochloride eye drops as a topical anesthetic, cotton was used to swab the conjunctival sac fluid. A home-made alkali burn mold was made according to the following procedure: the tip of a 200 µL pipette tip was cut horizontally 15 mm from the end; the reminder of the pipette tip was filled with enough cotton, so that cotton was exposed at the tip of the pipette tip and formed a flat and slightly convex surface with moderate tightness; the tip was sterilized by high temperatures before use; 20 µL of 1.0 M NaOH was added to the mold (circular, 3.0 mm diameter); and the mold was placed vertically in the center of the cornea of the right eye of each SD rats for 25 seconds to produce a corneal burn. The wound surface was rapidly washed with 20 mL 0.9% physiological saline for 1 min. Doxycycline eye drops were made by dissolving doxycycline powder (Sigma-Aldrich, St. Louis, MO, USA) in PBS. The doxycycline group was treated with 1.0 g·L⁻¹ doxycycline eye drops four times a day for 14 days, and the control group was treated with PBS in the same manner. Alkali burn occurred on day 0, and the animals were euthanized 3, 7, and 14 days after injury.

2.3. Corneal Opacity and Injury. The degree of corneal opacity was examined using a microscope on days 3, 7, and 14 after corneal alkali burn. The degree of hazy was scored clinically on the following 0–4 numerical scale: 0, clear cornea; 1, slight stromal opacity; 2, moderate stromal opacity; 3, severe corneal opacity with difficulty viewing the iris; and 4, opaque cornea without the ability to view the iris. Epithelial defect was assessed 3, 7, and 14 days after chemical injury by staining with 1% fluorescein and imaging the staining. Two independent masked observers analyzed the images. The area of the epithelial defect was calculated by Image-Pro Plus® software.

2.4. Real-Time PCR. Eight rats were randomly selected from each group on days 3, 7, and 14 after chemical injury, and the corneal tissue was aseptically removed along the corneal scleral margin. The corneal tissue was divided into two equal parts, and one portion was quickly stored in a −80°C freezer, and the other was homogenized in a 1.5 ml centrifuge tube containing cracking Buffer RL. Then, Trizol reagent (TaKaRa, Tokyo, Japan) was used to collect total RNA. The RNA was reverse-transcribed into cDNA using a PrimeScript RT Master Mix reverse transcription kit (TaKaRa, Tokyo, Japan). Real-time polymerase chain reaction (RT-PCR) was performed using Premix Ex Taq gene expression assays (TaKaRa, Tokyo, Japan). The following primers were used: GAPDH forward, TGAAGGTCCGTGTAAGCGATTTG; GAPDH reverse, GTTGAATTTGCCGTGAGTGGAGTC; TGF-β1 forward, TGAAGGTCGGTGTGAACGGATTTG; GAPDH reverse, CACGCCAGAA G. CT values were used for the relative quantification of the initial template. The final results are expressed as 2−ΔΔct.

2.5. Enzyme-Linked Immunosorbent Assay (ELISA). The other pieces of corneal tissue collected on days 3, 7, and 14 were removed from the −80°C freezer, homogenized in PBS, stored at −20°C overnight, frozen and thawed twice, and then centrifuged at 500 × g 4°C for 5 min in a low-temperature centrifuge. TGF-β1 and MMP-9 levels in the supernatant were quantified by ELISA according to the instructions of the kit (CUSABIO Biotech, Wuhan, China). The optical absorbance (OD) value of each well was measured at a wavelength of 450 nm with microplate reader. A standard curve was drawn using professional software.
(Curve Expert 1.4), and the OD values were used to determine the corresponding protein concentration from the standard curve.

2.6. Immunofluorescence Assay. Paraffin sections (5 μm) were processed for immunofluorescent staining for α-SMA. After high-pressure repair, the sections were blocked with 5% goat serum for 30 min. Then, the sections were incubated for 1 hr with a rabbit polyclonal antibody against α-smooth muscle actin (ab5694, 1:200; Abcam, Cambridge, MA, USA) at room temperature. A FITC-conjugated antibody against goat immunoglobulin (DyLight 649, 1:500; Fudebio-tech, Hangzhou, China) was added to the specimens at room temperature for 1 hr. An antifluorescence quenching sealant containing DAPI (Solarbio, Beijing, China) was used to seal and counterstaining the sections, and the nuclei were stained blue with DAPI dye. Doxycycline treatment reduced α-SMA expression in the alkali-burned corneas.

2.7. Western Blotting for α-SMA, TGF-β1, and NF-κB. The corneas treated with 1.0g L⁻¹ doxycycline eye drops or PBS for 3, 7, and 14 days were excised and homogenized in RIPA lysis buffer (Beyotime, Shanghai, China) containing proteinase inhibitors using an ultrasound homogenizer. Three corneas were used for each experimental condition. The samples were diluted with one part 4× sample buffer (Beyotime, Shanghai, China) and boiled for 5 min. The same amount of total protein from each cornea was separated by 8% SDS-PAGE and then transferred to PVDF membranes. The membranes were developed and photographed.

2.8. Statistical Analysis. The data are expressed as the mean ± standard deviation (SD). Student’s t-test was applied to identify the differences between the groups, and P values <0.05 were considered statistically significant.

3. Results

3.1. Degree of Corneal Opacity and Injury. Representative pictures of the injured corneas are shown in Figure 1(a). The corneal opacity score was lower in the doxycycline group than in the control group 7 and 14 days after chemical injury (P < 0.05) (Figure 1(b)). In addition, after 7 and 14 days, the corneal epithelial defects in the doxycycline group were also less severe than those in the control group (P < 0.05) (Figure 2).

3.2. Real-Time PCR. Real-time PCR showed that the levels of TGF-β1 mRNA were lower in the doxycycline group than in the control group 3, 7, and 14 days after corneal alkali burn (P < 0.05) (Figure 3(a)). However, MMP-9 mRNA expression was lower in the doxycycline group than in the control group 3 and 7 days after injury (P < 0.05) (Figure 3(b)). The difference between the two groups was no statistically significant 14 days after corneal alkali burn (P > 0.05).

3.3. ELISA. The TGF-β1 levels in the doxycycline group (71.18 ± 1.88, 78.13 ± 4.23, and 71.08 ± 3.59 pg/ml) were significantly lower than those in the control group (113.38 ± 5.80, 120.80 ± 5.67, and 103.46 ± 2.75 pg/ml) 3, 7, and 14 days after alkali burn (P < 0.05) (Figure 4(a)). At the same time, the MMP-9 levels in the doxycycline group (420.18 ± 46.36 and 767.63 ± 35.01 pg/ml) were lower than those in the control group (993.27 ± 26.96 and 1217.42 ± 25.05 pg/ml) 3 and 7 days after injury (P < 0.05) (Figure 4(b)). However, there was no statistically significant difference between doxycycline group (784.70 ± 24.92 pg/ml) and control group (807.56 ± 21.22 pg/ml) 14 days after chemical injury (P > 0.05).

3.4. Immunofluorescence. The immunofluorescent staining of α-SMA in the doxycycline and control groups is shown in Figure 5. The doxycycline group expressed less red fluorescence than that in the control group 3, 7, and 14 days after injury. In other words, the immunofluorescent staining for α-SMA was weaker in the doxycycline group than in the control group. The nuclei were stained blue with DAPI dye. Doxycycline treatment reduced α-SMA expression in the alkali-burned corneas.

3.5. Western Blotting. Western blot analysis was also used to quantify the levels of TGF-β1, α-SMA, and NF-κB expression. When normalized to GAPDH expression, the expression of these three proteins in the doxycycline group was significantly decreased compared to that in the control group 3, 7, and 14 days after chemical injury (Figure 6).

4. Discussion

The cornea is the refractive system of the eye and acts as a barrier. Chemical damage to the eye accounts for 11.5% and 22.1% of ocular injuries. Corneal scarring caused by corneal trauma and ulcers is the leading contributor to corneal blindness [27, 28]. Currently, penetration and lamellar keratoplasty are the main clinical methods for treating corneal scars. However, due to the lack of cornea donors and for economic reasons, many patients cannot receive surgical treatment and eventually lose their vision. This emphasizes the need for developing new and more effective treatment strategies.

In recent years, the application of doxycycline has been widely investigated in ophthalmology. Peng et al. [29] treated laser-injured mice with intraperitoneal injections of doxycycline, and the results indicated that doxycycline can...
inhibit fibrosis in choroidal neovascularization. Other studies have also shown that doxycycline enhances allograft survival in alkali-burned mouse corneas by inhibiting corneal neovascularization and inflammation in the corneal bed [30]. Wang et al. [31] treated corneal erosion syndrome patients with a combination of oral doxycycline and topical corticosteroids, and 71% of patients were symptom-free. McElvanney [32] treated pseudomonas keratitis with oral doxycycline, and the results suggested that doxycycline may help stabilize corneal rupture and prevent subsequent perforation. Many studies have indicated that doxycycline may accelerate the healing of corneal wounds and inhibit the neovascularization and inflammation of the cornea after alkali burn [26, 33]. Our previous studies have investigated the effects of doxycycline on corneal neovascularization and inflammation after alkali burn [34, 35]. However, the molecular mechanism of doxycycline in corneal healing is unknown. In our current experiment, we explored the effect of doxycycline on TGF-β1, MMP-9, α-SMA, and NF-κB expression to clarify its mechanism of action in corneal scarring.

Corneal wound healing is a complicated process involving molecular cascade events. The key to this healing is re-epithelialization, which involves keratinocyte

![Image](image-url)
proliferation, migration, differentiation, and extracellular matrix remodeling [36]. There are three dominant cell types in the cornea: surface epithelial cells, stromal keratocytes, and endothelial cells. These cells have common mechanisms to promote wound healing, including cell migration and proliferation, the involvement of growth factors and cytokines, and extracellular matrix (ECM) remodeling [36, 37]. In this study, the cornea presented with epithelial defects, edema, and unclear iris texture on day 3 after corneal alkali burn. The corneal opacity was lower in the doxycycline group than in the control group 7 and 14 days after chemical injury, and the cornea was almost transparent in the doxycycline group on the 14th day (Figure 1(a)). Doxycycline treatment also improved corneal wound healing (Figure 2(a)).

TGF-β1 is abundantly present in human tears, which are secreted by the lacrimal glands and are produced by epithelial cells and inflammatory cells located on the surface of the eye [38, 39]. When the cornea is injured, due to the absence of a basement membrane, TGF-β1 penetrates into the underlying stroma and initiates the differentiation of keratocyte subsets into myofibroblasts [40]. This process is

---

**Figure 2:** (a) Slit-lamp photographs of fluorescein-stained corneas in the doxycycline group and the control group 3, 7, and 14 days after corneal alkali burn. (b) The corneal epithelial defect areas percentage of two groups on days 3, 7, and 14 after corneal alkali burn. There was a significant difference on days 7 and 14 after corneal alkali burn between two groups ($P < 0.05$). *Statistically significant; data are expressed as mean ± SD, $n = 8$. 

---

**Journal of Ophthalmology** 5
key to the contraction and closure of corneal wounds [41]. However, the overexpression of TGF-β1 aggravates corneal damage, resulting in the accumulation of myofibroblasts in the stromal layer. This is believed to be the main cause of corneal haze postinjury [42]. The results of RT-PCR, ELISA, and Western blotting for TGF-β1 indicated that the expression of TGF-β1 in the cornea was noticeable after chemical injury. Compared with that in the control group, TGF-β1 expression was decreased in the doxycycline group on days 3, 7, and 14 after injury. Meanwhile, the results of immunofluorescent staining and Western blotting for α-SMA expression showed the same trend as that of TGF-β1 expression in the doxycycline group and the control group, which indicated that doxycycline inhibited the expression of TGF-β1 and α-SMA. In other words, doxycycline suppressed the expression of TGF-β1 and the formation of corneal scars.

MMP-9 plays a role in many ocular physiological processes, including angiogenesis and wound healing [43], and it has been found to be expressed only in rats with corneal injury but not in normal corneal stroma [44]. The presence of MMP-9 has been identified in the tears of patients with corneal alkali burns [45]. Furthermore, MMP-9 has been shown to promote the migration of basal epithelial cells, and its expression pattern is consistent with the remodeling of the subepithelial basement membrane region [46]. Kim et al. [47] treated primary human corneal epithelial cells stimulated by TGF-β1 with doxycycline, and the results showed that doxycycline inhibited the level of MMP-9 expression. In the present study, MMP-9 expression was also decreased in the doxycycline group, and thus, the subepithelial basement membrane may have been more intact in the doxycycline group than in the control group. On the other hand, the
Figure 5: Immunofluorescence staining in the doxycycline group and the control group 3, 7, and 14 days after corneal alkali burn. DAPI was used for nuclear staining (blue). Immunofluorescent staining for $\alpha$-SMA was weaker than in the control group 3, 7, and 14 days after injury.

Figure 6: Continued.
delayed corneal wound healing in the control group may have been due to the high expression of MMP-9.

NF-κB is a major transcription factor that regulates many biological processes and is mainly involved in corneal wound healing, inflammation, angiogenesis, and the stress response [48]. Wilson et al. [49] found that the NF-κB ligand is increased in the epithelium after corneal scraping and is also expressed in cultured corneal fibroblasts. Taheri and Bazan [16] showed that increasing the binding of NF-κB to MMP-9 promotes upregulation of the MMP-9 expression in human corneal epithelial cells. However, Shin et al. [20] reported that doxycycline inhibited TGF-β1-induced myofibroblasts via NF-κB signaling pathways. In our study, the Western blot results showed that the expression of NF-κB was lower in the doxycycline group than in the control group, which was similar to the pattern of expression of MMP-9 and TGF-β1. Therefore, we suspect that doxycycline may inhibit the expression of MMP-9 and TGF-β1 during corneal wound healing through NF-κB signaling pathways.

In conclusion, treatment with doxycycline eye drops may accelerate wound healing in corneal tissue after alkali burn, and it may decrease corneal stromal haze by inhibiting MMP-9 and TGF-β1 expression. Doxycycline may reduce TGF-β1-induced myofibroblast transdifferentiation through the NF-κB signaling pathway.

Data Availability
The data used to support the findings of this study are included within the article.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
The authors would like to thank Wen-jin Zou for critically reviewing the manuscript. This study was edited by American Journal Experts. The work was supported by the National Natural Science Foundation of China (No.: 801160119), the Natural Science Foundation of Guangxi Zhuang Autonomous Region (2017GXNSFAA198347), and the Natural Science Foundation of Guangxi Zhuang Autonomous Region (2016GXNSFAA380280).

References
[1] J. D. Welling, E. C. Pike, and T. F. Mauger, "Alkali burn of the ocular surface associated with a commonly used antifog agent for eyewear," Cornea, vol. 35, no. 2, pp. 289–291, 2016.
[2] Y. Ke, Y. Wu, X. Cui et al., "Polysaccharide hydrogel combined with mesenchymal stem cells promotes the healing of corneal alkali burn in rats," PLoS One, vol. 10, no. 3, Article ID e0119725, 2015.
[3] M. Ishizaki, G. Zhu, T. Haseba, S. S. Shafer, and W. W. Kao, "Expression of collagen I, smooth muscle alpha-actin, and vimentin during the healing of alkali-burned and lacerated corneas," Investigative Ophthalmology & Visual Science, vol. 34, no. 12, pp. 3320–3328, 1993.
[4] S. Nakao, Y. Hata, M. Miura et al., "Dexamethasone inhibits interleukin-1β-induced corneal neovascularization," The American Journal of Pathology, vol. 171, no. 3, pp. 1058–1065, 2007.
[5] A. A. M. Torricelli and S. E. Wilson, "Cellular and extracellular matrix modulation of corneal stromal opacity," Experimental Eye Research, vol. 129, pp. 151–160, 2014.
[6] J. V. Jester and J. Ho-Chang, "Modulation of cultured corneal keratocyte phenotype by growth factors/cytokines control in vitro contractility and extracellular matrix contraction," Experimental Eye Research, vol. 77, no. 5, pp. 581–592, 2003.
[7] S. Sriram, J. A. Tran, and J. D. Zieske, "Cornea as a model for testing CTGF-based antiscarring drugs," Bone and Tissue Regeneration Insights, vol. 7, 2016.
[8] A. Tandon, J. C. K. Tovey, A. Sharma, R. Gupta, and R. R. Mohan, "Role of transforming growth factor Beta in corneal function, biology and pathology," Current Molecular Medicine, vol. 10, no. 6, pp. 565–578, 2010.
[9] M. Chen, H. Matsuda, L. Wang et al., "Pretranscriptional regulation of Tgf-β1 by PI polyamide prevents scarring and
accelerates wound healing of the cornea after exposure to alkali."

[10] H. Takahashi, T. Igarashi, C. Fujimoto, N. Ozaki, and M. Ishizaki, "Immunohistochemical observation of anniotic membrane patching on a corneal alkali burn in vivo," Japanese Journal of Ophthalmology, vol. 51, no. 1, pp. 3–9, 2007.

[11] S. Saika, "TGF-beta signal transduction in corneal wound healing as a therapeutic target," Cornea, vol. 23, no. 8, pp. S25–S30, 2004.

[12] S. Saika, K. Ikeda, O. Yamanaka et al., "Expression of Smad7 in mouse eyes accelerates healing of corneal tissue after exposure to alkali," The American Journal of Pathology, vol. 166, no. 5, pp. 1405–1418, 2005.

[13] M. A. Behzadian, X. L. Wang, L. J. Windsor, N. Ghaly, and R. B. Caldwell, "TGF-beta increases retinal endothelial cell permeability by increasing MMP-9: possible role of glial cells in endothelial barrier function," Investigative Ophthalmology & Visual Science, vol. 42, no. 3, pp. 853–859, 2001.

[14] N. Ebihara, M. Nakayama, T. Tokura, H. Ushio, and A. Murakami, "Expression and function of fibroblast growth factor-inducible 14 in human corneal myofibroblasts," Experimental Eye Research, vol. 89, no. 2, pp. 256–262, 2009.

[15] J. T. Daniels, G. Geerling, R. A. Alexander, G. Murphy, P. T. Khaw, and U. Saarialho-Kere, "Temporal and spatial expression of matrix metalloproteinases during wound healing of human corneal tissue," Experimental Eye Research, vol. 77, no. 6, pp. 653–664, 2003.

[16] F. Taheri and H. E. P. Bazan, "Platelet-activating factor over-turns the transcriptional repressor disposition of Sp1 in the expression of MMP-9 in human corneal epithelial cells," Investigative Ophthalmology & Visual Science, vol. 48, no. 5, p. 1931, 2007.

[17] J. V. Jester, T. Moller-Pedersen, J. Huang et al., "The cellular basis of corneal transparency: evidence for 'corneal crystals'," Journal of Cell Science, vol. 112, no. 5, pp. 613–622, 1999.

[18] A. Smith and S. D. Cook, "Doxycycline--a role in ocular surface repair," British Journal of Ophthalmology, vol. 88, no. 5, pp. 619–625, 2004.

[19] X.-F. Hua, X.-H. Li, M.-M. Li et al., "Doxycycline attenuates paraquat-induced pulmonary fibrosis by downregulating the TGF-β signaling pathway," Journal of Thoracic Disease, vol. 9, no. 11, pp. 4376–4386, 2017.

[20] J.-M. Shin, J.-H. Park, J.-H. Park, and H.-M. Lee, "Doxycycline inhibits TGF-β1-induced extracellular matrix production in nasal polyp-derived fibroblasts," International Forum of Allergy & Rhinology, vol. 6, no. 3, pp. 256–263, 2016.

[21] J. Caton and M. E. Ryan, "Clinical studies on the management of periodontal diseases utilizing sub-antimicrobial dose doxycycline (SDD)," Pharmacological Research, vol. 63, no. 2, pp. 114–120, 2011.

[22] A. L. Moore, H. E. desJardins-Park, B. A. Duoto et al., "Doxycycline reduces scar thickness and improves collagen architecture," Annals of Surgery, p. 1, 2018.

[23] J. H. Li, D. G. Ezra, M. J. Burton, and M. Bailly, "Doxycycline prevents matrix remodeling and contraction by trichiasis-derived conjunctival fibroblasts," Investigative Ophthalmology & Visual Science, vol. 54, no. 7, pp. 4675–4682, 2013.

[24] R. A. Ralph, "Tetracyclines and the treatment of corneal stromal ulceration," Cornea, vol. 19, no. 3, pp. 274–277, 2000.

[25] F. Bian, F. S. A. Pelegrino, J. T. Henriksson et al., "Differential effects of dexamethasone and doxycycline on inflammation and MMP production in murine alkali-burned corneas associated with dry eye," The Ocular Surface, vol. 14, no. 2, pp. 242–254, 2016.

[26] W. Su, Z. Li, M. Lin et al., "The effect of doxycycline temperature-sensitive hydrogel on inhibiting the corneal neovascularization induced by BFGF in rats," Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 249, no. 3, pp. 421–427, 2011.

[27] C. Pratoomsoot, H. Tanioka, K. Hori et al., "A thermoresponsive hydrogel as a biosynthetic bandage for corneal wound repair," Biomaterials, vol. 29, no. 3, pp. 272–281, 2008.

[28] G. Clare, H. Suleman, C. Bunce, and H. Dua, "Anniotic membrane transplantation for acute ocular burns," Cochrane Database of Systematic Reviews, vol. 9, Article ID CD009379, 2012.

[29] X. Peng, H. Xiao, M. Tang et al., "Mechanism of fibrosis inhibition in laser induced choroidal neovascularization by doxycycline," Experimental Eye Research, vol. 176, pp. 88–97, 2018.

[30] S. Ling, W. Li, L. Liu et al., "Allograft survival enhancement using doxycycline in alkali-burned mouse corneas," Acta Ophthalmologica, vol. 91, no. 5, pp. e369–e378, 2013.

[31] L. Wang, H. Tsang, and M. Coroneo, "Treatment of recurrent corneal erosion syndrome using the combination of oral doxycycline and topical corticosteroid," Clinical & Experimental Ophthalmology, vol. 36, no. 1, pp. 8–12, 2008.

[32] M. McElvanney, "Doxycycline in the management of pseudomonal corneal melting," Eye & Contact Lens: Science & Clinical Practice, vol. 29, no. 4, pp. 258–261, 2003.

[33] L. Dan, Y. Shi-long, L. Miao-li et al., "Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model of angiogenesis," Current Eye Research, vol. 33, no. 8, pp. 653–660, 2008.

[34] W. J. Zou, Z. G. Liu, M. L. Liu et al., "Comparison of inhibitory effects of doxycycline and dexamethasone on corneal neovascularization in rats with corneal alkali burn," Recent Advances in Ophthalmology, vol. 33, no. 8, pp. 701–704, 2013.

[35] J. B. Zhao, W. J. Zou, and X. Y. Fu, "Doxycycline inhibits the infiltration of inflammatory cells in rat alkali burn corneas," International Eye Science, vol. 13, no. 6, pp. 1090–1092, 2013.

[36] A. V. Ljubimov and M. Saghizadeh, "Progress in corneal wound healing," Progress in Retinal and Eye Research, vol. 49, pp. 17–45, 2015.

[37] M. Saghizadeh, A. A. Kramerov, C. N. Svendsen, and A. V. Ljubimov, "Concise review: stem cells for corneal wound healing," Stem Cells, vol. 35, no. 10, pp. 2105–2114, 2017.

[38] K. Nishida, C. Sotozono, W. Adachi, S. Yamamoto, N. Yokoi, and S. Kinoshita, "Transforming growth factor-β1, -β2 and -β3 mRNA expression in human cornea," Current Eye Research, vol. 14, no. 3, pp. 235–241, 1995.

[39] Y. Honma, K. Nishida, C. Sotozono, and S. Kinoshita, "Effect of transforming growth factor-β1 and -β2 on vitroKrabbit corneal epithelial cell proliferation promoted by epidermal growth factor, keratinocyte growth factor, or hepatocyte growth factor," Experimental Eye Research, vol. 65, no. 3, pp. 391–396, 1997.

[40] C. S. Medeiros, G. K. Marino, M. R. Saithiago, and S. E. Wilson, "The corneal basement membranes and stromal fibrosis," Investigative Ophthalmology & Visual Science, vol. 59, no. 10, pp. 4044–4053, 2018.

[41] S. Saika, O. Yamanaka, T. Sumioka et al., "Transforming growth factor β signal transduction: a potential target for maintenance/restoration of transparency of the cornea," Eye & Contact Lens: Science & Clinical Practice, vol. 36, no. 5, pp. 286–289, 2010.
expressed during corneal epithelial wound repair,” *Investigative Ophthalmology & Visual Science*, vol. 42, no. 7, pp. 1465–1471, 2001.

[43] Y. Kawashima, S. Saika, T. Miyamoto et al., “Matrix metalloproteinases and tissue inhibitors of metalloproteinases of fibrous humans lens capsules with intraocular lenses,” *Current Eye Research*, vol. 21, no. 6, pp. 962–967, 2000.

[44] M. Matsubara, M. T. Girard, C. L. Kublin, C. Cintron, and M. E. Fini, “Differential roles for two gelatinolytic enzymes of the matrix metalloproteinase family in the remodelling cornea,” *Developmental Biology*, vol. 147, no. 2, pp. 425–439, 1991.

[45] M. Gao, W. Sang, F. Liu et al., “High MMP-9 expression may contribute to retroprosthetic membrane formation after KPro implantation in rabbit corneal alkali burn model,” *Journal of Ophthalmology*, vol. 2016, Article ID 1094279, 8 pages, 2016.

[46] R. Mohan, W. B. Rinehart, P. Bargagna-Mohan, and M. E. Fini, “Gelatinase B/lacZ Transgenic mice, a model for mapping gelatinase B expression during developmental and injury-related tissue remodeling,” *Journal of Biological Chemistry*, vol. 273, no. 40, pp. 25903–25914, 1998.

[47] H.-S. Kim, L. Luo, S. C. Pflugfelder, and D.-Q. Li, “Doxycycline inhibits TGF-β1-induced MMP-9 via smad and MAPK pathways in human corneal epithelial cells,” *Investigative Ophthalmology & Visual Science*, vol. 46, no. 3, pp. 840–848, 2005.

[48] W. Lan, A. Petznick, S. Heryati, M. Rifada, and L. Tong, “Nuclear factor-κB: central regulator in ocular surface inflammation and diseases,” *The Ocular Surface*, vol. 10, no. 3, pp. 137–148, 2012.

[49] S. E. Wilson, R. R. Mohan, M. Netto et al., “RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing,” *Investigative Ophthalmology & Visual Science*, vol. 45, no. 7, pp. 2201–2211, 2004.